Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 14 articles:
HTML format

Single Articles

    May 2023
  1. DMUCHOWSKA DA, Obuchowska I, Konopinska J
    Immediate versus delayed sequential bilateral cataract surgery.
    Lancet. 2023 May 15:S0140-6736(23)00692-X. doi: 10.1016/S0140-6736(23)00692.

  2. SPEKREIJSE L, Simons R, Winkens B, van den Biggelaar F, et al
    Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
    Lancet. 2023 May 15:S0140-6736(23)00525-1. doi: 10.1016/S0140-6736(23)00525.
    PubMed     Abstract available

    March 2023
  3. GUYMER RH, Campbell TG
    Age-related macular degeneration.
    Lancet. 2023 Mar 27:S0140-6736(22)02609-5. doi: 10.1016/S0140-6736(22)02609.
    PubMed     Abstract available

    December 2022
  4. CICINELLI MV, Buchan JC, Nicholson M, Varadaraj V, et al
    Lancet. 2022 Dec 21:S0140-6736(22)01839-6. doi: 10.1016/S0140-6736(22)01839.
    PubMed     Abstract available

    September 2022
  5. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
    Lancet. 2022;400:808-809.

  6. DYBALL S, Parker B, Bruce IN
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
    Lancet. 2022;400:807-808.

    August 2022
  7. BAGENAL J, Khanna R, Hawkes S
    Not misogynistic but myopic: the new women's health strategy in England.
    Lancet. 2022 Aug 10. pii: S0140-6736(22)01486.

    January 2022
  8. WYKOFF CC, Abreu F, Adamis AP, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00018.
    PubMed     Abstract available

  9. HEIER JS, Khanani AM, Quezada Ruiz C, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00010.
    PubMed     Abstract available

  10. CHIA MA, Keane PA
    Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00105.

  11. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.

  12. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    PubMed     Abstract available

  13. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.

    October 2021
  14. AYADI K, Gallaoui S, Ben Nsir A
    Pituitary apoplexy, but not as we thought: a xanthogranuloma rather than an adenoma.
    Lancet. 2021;398:e16.

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.